Dr. Khouri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
# CA6
Cleveland, OH 44195Phone+1 216-296-5539
Summary
- Dr. Jack Khouri is a hematologist/oncologist in Cleveland, OH and is affiliated with Cleveland Clinic. He received his medical degree from University of Balamand Faculty of Medicine and has been in practice 5 years. He specializes in hematologic oncology, bone marrow transplantation and apheresis medicine.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2016 - 2019
Tufts Medical CenterResidency, Internal Medicine, 2013 - 2016
University of Balamand Faculty of MedicineClass of 2012
Certifications & Licensure
OH State Medical License 2016 - 2026
MA State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow of the American College of Physicians ACP, 2024
- Teacher of the Year Award Cleveland Clinic Hematology/Medical Oncology Fellowship, 2020
- Excellence in Teaching Cleveland Clinic Internal Medicine Residency Program, 2018
- Join now to see all
Clinical Trials
- A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis Start of enrollment: 2021 Aug 30
- APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2021 Dec 23
- Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Start of enrollment: 2023 Feb 13
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSafety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.Surbhi Sidana, Krina K Patel, Lauren C Peres, Radhika Bansal, Mehmet H Kocoglu
Blood. 2025-01-02 - Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel
Blood Cancer Journal. 2024-12-05 - 2 citationsSafety and efficacy of B cell maturation antigen-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis.Utkarsh Goel, Danai Dima, James Davis, Nausheen Ahmed, Hira Shaikh
European Journal of Haematology. 2024-12-01
Journal Articles
- AL Amyloidosis: Diagnosis and Therapeutic AdvancesJack Khouri, Clinical Hematology Update, New England Journal of Medicine Group, 12/2023
- Neutropenic Fever During Peripheral Blood Progenitor Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Increased Apheresis Collection DaysMat Kalaycio, Robert Dean, Jack Khouri, Brad Pohlman, Aleksandr Lazaryan, Edward Copelan, Steven Andresen, Ronald Sobecks, Hien Liu, Journal of Clinical Apheresis
- Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection daysKhouri J, Rybicki L, Majhail N, Kalaycio M, Copelan E, Pohlman B, Hill B, Dean R, Lazaryan A, Hamilton B, Andresen S, Sobecks R, Bolwell B, Liu H, Journal of Clinical Apheresis, 11/2017
Abstracts/Posters
- Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat AnalysisJack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Rapid Infusion Daratumumab Is Safe in Patients with AL AmyloidosisJack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- External Validation of the Impede VTE Risk Score in Newly Diagnosed Multiple Myeloma (MM) PatientsJack Khouri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- ASH 2024 | Outcomes of teclistamab in RRMM with prior exposure to BCMA-directed therapyDecember 2024
- ISA 2024 | Current approaches for managing R/R AL amyloidosisMay 2024
- ISA 2024 | Exploring the next era of treating AL amyloidosis: role of birtamimabMay 2024
- Perspective: Teclistamab confers durable benefit in advanced multiple myeloma. Haelio. June 17, 2022June 2022
- Unprecedented Advances Fuel Progress in the Treatment of AL AmyloidosisFebruary 2022
- Join now to see all
Press Mentions
Cleveland Clinic Trial Seeks Life-Saving Treatment for Rare DiseaseMarch 14th, 2024- Optimizing Sequencing of BCMA-Directed Therapies in MyelomaDecember 20th, 2024
Real-World Study Examines Optimal Sequencing and Timing of Treatments for Relapsed/Refractory Multiple MyelomaDecember 11th, 2024- Join now to see all
Grant Support
- Phase II trial of siltuximab for cytokine release syndrome prophylaxis prior to treatment with teclistamab in relapsed or refractory multiple myeloma (RRMM)Recordati2024–Present
Professional Memberships
- Member
- Member
- Member
Other Languages
- French, Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
